To Compare The Clinical Efficacy Of Two Drugs In The Treatment Of Persistent Human Papillomavirus Infection

Objective: to compare the clinical efficacy of two drugs in the treatment of persistent human papillomavirus infection.Methods: from October 2017 to September 2019,140 patients with high risk human papillomavirus(HPV)infection diagnosed in the first affiliated hospital of xinjiang medical university were randomly divided into group A(68)and group B(72).Group A was treated with anti-hpv biological protein dressing,and group B was treated with recombinant human interferon a-2b gel.Comparison of the two groups of human papillomavirus negative conversion rate,cervical fluid-based cytological indicators of improvement,drug adverse reactions.Results: 1.The proportion of high-risk HPV infection was 77.1 % between 30 and 50 years old.2.There was no statistically significant difference in the negative conversion rate of human papillomavirus between the two groups(51.5% in group A and 36.1% in group B)at 1 month after treatment(P>0.05).3 months after treatment,the negative conversion rate of human papillomavirus(75.0% in group A and 48.6% in group B)was statistically significant(P<0.05).3.There was no statistically significant difference in the negative conversion rate of human papillomavirus among different cervical lesions in group A(76.1% for chronic cervicitis and 73.1% for low-grade cervical intraepithelial neoplasia)(p>0.05).4.There were statistically significant differences in the negative conversion rate of human papillomavirus(HPV)in different cervical lesions in group A(76.1% for chronic cervicitis and 73.1% for low-grade cervical intraepithelial neoplasia)and that in group B(53.1% for chronic cervicitis and 40.0% for low-grade cervical intraepithelial neoplasia)(P<0.05).5.There was no statistically significant difference in hpv16/18 Yin conversion rate between group A(44.4%)and group B(33.3%)(P>0.05).6.Cervical fluid-based cytology in group A showed statistically significant differences with that in group B(P<0.05).7.The incidence of adverse reactions in group A(0.0%)was significantlydifferent from that in group B(8.0%)(P<0.05).Conclusion: 1.The efficacy of anti-hpv biological protein dressing on chronic cervicitis or low grade cervical intraepithelial neoplasia combined with high-risk HPV infection is better than recombinant human interferon a-2b gel.2.Especially after 3 months of withdrawal,the anti-hpv biological protein dressing has a higher negative conversion rate;3.Anti-hpv biological protein dressing can better improve the cervical liquid-based cytological indicators;4.Anti-hpv biological protein dressings are safe.